Home

nevidím kurzíva peer nmd pharma thomas hilm pás uvoľnene sliz

Other news — NMD Pharma
Other news — NMD Pharma

NMD Pharma Raises €35 Million in a new Financing
NMD Pharma Raises €35 Million in a new Financing

Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter

Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter

NMD Pharma - PIR International
NMD Pharma - PIR International

Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter

NMD Pharma - PIR International
NMD Pharma - PIR International

NMD Pharma expands its US presence — NMD Pharma
NMD Pharma expands its US presence — NMD Pharma

NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma
NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma

Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter

Management team — NMD Pharma
Management team — NMD Pharma

Other news — NMD Pharma
Other news — NMD Pharma

NMD Pharma - PIR International
NMD Pharma - PIR International

Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn

NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare  Neuromuscular Disorders - Global Genes
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes

Other news — NMD Pharma
Other news — NMD Pharma

Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter

Management team — NMD Pharma
Management team — NMD Pharma

Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn

Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn

Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn

Other news — NMD Pharma
Other news — NMD Pharma